Filing Flows › Denali Therapeutics (DNLI) › Q2 2026
Denali Therapeutics (DNLI) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 6, 2026
Denali Therapeutics (DNLI) reported revenue of $3.6M for the second quarter 2026 (Q2 2026).
Denali Therapeutics, Q2 2026: revenue $3.6M, net loss $128M, operating cash flow −$97.0M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $3.6M | — | — |
| Operating profit | −$131M | — | — |
| Net earnings | −$128M | — | — |
| Operating cash flow | −$97.0M | — | — |
What changed
Revenue was $3.6M in Q2 2026.
Operating costs exceeded revenue by $130.5M, an operating margin of -3622.1%. The quarter ended with a net loss of $127.6M.
Operating cash flow was −$97.0M. Non-cash charges added back $3.6M of depreciation and amortization and $22.9M of share-based compensation. Capital expenditures of $805K exceeded it, leaving free cash flow of −$97.8M.
Questions
What was Denali Therapeutics' revenue in the second quarter 2026?
Denali Therapeutics (DNLI) reported revenue of $3.6M for the second quarter 2026 (Q2 2026).